← Leaderboards
Edward A Hirschowitz
University Of Kentucky
$2,686,606
Attributed
$2,760,856
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $576.3K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,760,856 · 5
By mechanism
R01$1,811,637 · 1
R21$603,827 · 1
R41$177,279 · 1
R03$148,500 · 1
M01$19,613 · 1
Top collaborators
- Marc Knecht2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Qing-Bai She$4,718,039
- Eric B. Durbin$4,591,696
- Marc Knecht$74,250
- Thomas Tucker$13,374,965
- Daniel Ray Plaugher$124,546
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMalignant Neoplasm Of LungHeterogeneityCostDesignMalignant NeoplasmsProteinsMeasurementSamplingValidationTumorClinical ApplicationDetectionCancer PatientAntibodiesBlood TestsBiomarkerAutoantibodiesCost EffectivenessAppearanceDiagnosisBenignCase ControlBase
Grant awards (14)
Bionanoconjugates for Detection of Circulating Tumor Cells in Lung Cancer$74,250
R03 · FY2012 · CA · contact PI
Bionanoconjugates for Detection of Circulating Tumor Cells in Lung Cancer$74,250
R03 · FY2011 · CA · contact PI
Autoantibodies in NSCLC as Markers for Disease$256,375
R01 · FY2010 · CA · contact PI
Autoantibodies in NSCLC as Markers for Disease$256,375
R01 · FY2009 · CA · contact PI
Autoantibodies in NSCLC as Markers for Disease$256,375
R01 · FY2008 · CA · contact PI
Autoantibodies in NSCLC as Markers for Disease$256,375
R01 · FY2007 · CA · contact PI
Auto-antibody profiling of non-small cell lung cancer$177,279
R41 · FY2006 · CA · contact PI
Autologous Dendritic Cell Vaccines in NSCLC$301,965
R21 · FY2005 · CA
Autoantibodies in NSCLC as Markers for Disease$262,194
R01 · FY2005 · CA
THERAPEUTIC EFFECTS OF COX-2 INHIBITORS IN NON-SMALL CELL LUNG CANCER$12,091
M01 · FY2005 · RR
Autologous Dendritic Cell Vaccines in NSCLC$301,862
R21 · FY2004 · CA
Autoantibodies in NSCLC as Markers for Disease$262,194
R01 · FY2004 · CA
Therapeutic Effects of COX-2 Inhibitors in Non-Small Cell Lung Cancer$7,522
M01 · FY2004 · RR
Autoantibodies in NSCLC as Markers for Disease$261,749
R01 · FY2003 · CA